Vancomycin-resistant enterococci: A rising challenge to global health

Authors

Faiza Iqbal, Kasturba Medical College, Manipal
Arya Alocious, Nehru College of Pharmacy
Selin C. Joy, Amrita Institute of Medical Sciences India
Elstin Anbu Raj Stanly, Prasanna School of Public Health

Document Type

Article

Publication Title

Clinical Epidemiology and Global Health

Abstract

Introduction: Improper antibiotic use triggers outbreaks of hospital-acquired VRE infections. Relevant studies were gathered from Scopus, and PubMed. Over two decades, prevalence of VRE in humans and animals grew from 0.05 % to 99.0 % globally and from 1.0 % to 45.6 % in India. Identifying VRE at the species level helps identify acquired/intrinsic resistance. Results and conclusion: VRE infections, especially bloodstream infections, inflict significant mortality (60-70%-global; 23%-India) and economic burden ($539 million). Linezolid and daptomycin are frequently used without adequate clinical trial evidence. India lacks studies on prevalence, mortality and cost, which needs political will, public-private partnership, and prioritizing public health.

DOI

10.1016/j.cegh.2024.101663

Publication Date

7-1-2024

Recommended Citation

Iqbal, Faiza; Alocious, Arya; Joy, Selin C.; and Stanly, Elstin Anbu Raj, "Vancomycin-resistant enterococci: A rising challenge to global health" (2024). Open Access archive. 10298.
https://impressions.manipal.edu/open-access-archive/10298